Viral Mucosal Reprogramming

Healthy Clinical Trial

— VMR  

Official title:

Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma VIRAL MUCOSAL REPROGRAMMING

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05331170
• Other study ID #: U01-UWM-01
• Secondary ID: 19-0240
• Status: Recruiting
• Phase: Phase 2
• Start date: April 27, 2023
• Est. completion date: May 1, 2027

Study information

• Verified date: May 2023
• Source: The University of Texas Medical Branch, Galveston
• Contact: Lisa Sweeney, RN
• Phone: 409-747-5871
• Email: lanemeth[@]utmb.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a mechanistic, controlled, open-label, single-site study to evaluate the effects of RG-RV16 inoculation on airway mucosal gene expression and airway remodeling in 25 healthy controls (HC), in 25 allergic rhinitis subjects (AR) with cat dander allergy, and in 25 allergic asthmatic subjects (AA) with cat dander allergy. Three groups (HC, AR, and AA) will undergo screening to establish clinical history, will undergo pulmonary function testing (spirometry), and will have blood drawn for clinical characterization (IgE, , ImmunoCAP, CBC and differential), and for assessing the presence of existing neutralizing antibody against RV16. Only those who meet criteria will be permitted to continue into the interventional and run-out phases of the study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: May 1, 2027
• Est. primary completion date: May 1, 2027
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Healthy Normal Control Group

1. Subject must be able to understand and provide informed consent

2. Age: 18-60 inclusive

3. Sex: M or F

4. No history of asthma, COPD, rhinitis, or other clinically important respiratory disease

5. Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote.

6. No history of diabetes or cardiovascular disease

7. Negative ImmunoCAP test to regionally relevant allergen panel obtained at Screening. Alternatively, documented history of a negative skin test or negative specific IgE obtained within the past 12 months.

Allergic Rhinitis Group

1. Subject must be able to understand and provide informed consent

2. Age: 18-60 inclusive

3. Sex: M or F

4. No history of asthma, COPD, or other clinically important respiratory disease

5. Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote

6. No history of diabetes or cardiovascular disease

7. History of rhinitis, physician diagnosed, plus one of the following criteria within the past 12 months

8. Seasonal or perennial nasal congestion or sneezing

9. Seasonal or perennial conjunctival infection or watering

10. No evidence of airway obstruction (FEV1:FVC = lower limit of normal)

11. Positive ImmunoCAP test to cat. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criterion. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.

Allergic Asthma Group

Inclusion Criteria

1. Subject must be able to understand and provide informed consent

2. Age: 18-60 inclusive

3. Sex: M or F

4. No history of COPD or other clinically important respiratory disease other than asthma

5. Non-smoker, or ex-smoker with <10 pack years, at least 5 years remote

6. No history of diabetes or cardiovascular disease

7. History of mild-moderate asthma, physician diagnosed, plus one of the following criteria within the past 12 months

1. Airway obstruction (FEV1: FVC <0.6) that is significantly (at least 12% change from baseline, ATS criteria) reversible after 4 puffs of albuterol (obtained at Screening Visit or documented historical testing performed with the past 12 months)

2. Requiring ICS for control of asthma for at least 30 days within the past 12 months

8. Positive ImmunoCAP test to cat dander. Documented history at any time of a positive skin test or a specific IgE measure at least Level 2 reactivity will meet this criteria. Subjects must have cat in home, have regular exposure to cat dander, or live in a home where a cat has lived within the past 6 months.

9. Results of the CBC do not show clinically important abnormalities

Exclusion Criteria:

Healthy Group Normal Group

1. Inability or unwillingness of a participant to comply with study protocol

2. Currently taking inhaled corticosteroids, leukotriene modifier, or antihistamines for respiratory disease.

3. Neutralizing Ab to RV16 greater than or equal to 1:8

4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at the screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.

5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV).

6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).

Allergic Rhinitis Group

1. Inability or unwillingness of a participant to comply with study protocol

2. Currently using inhaled steroids, or oral montelukast for respiratory disease

3. Neutralizing Ab to RV16 greater than or equal to 1:8

4. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening visit. Pregnancy testing may be conducted prior to procedures as well at various times in the study.

5. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .

6. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).

7. Subjects who have received immunosuppressive treatment within the last 12 months

8. BMI is greater than 35

9. History of symptoms consistent with a viral URI within the past 21 days

10. Results of the CBC do not show clinically important abnormalities

11. Family history or medical history of liver disease or bleeding disorders

12. Have not received systemic corticosteroids for 3months prior to Screening

13. Antiplatelet agents other than aspirin

14. Subjects who have a positive COVID-19 test will be excluded for 8 weeks

Allergic Asthma Group

1. Inability or unwillingness of a participant to comply with study protocol

2. Currently taking medications for respiratory diseases other than ICS, montelukast, or rescue albuterol or LABAs.

3. Neutralizing Ab to RV16 greater than or equal to 1:8

4. FEV1: FVC ratio less than 0.6, or FEV1 less than 60% predicted

5. Recent (<30 days) exacerbation of asthma requiring systemic corticosteroids

6. ICS greater than fluticasone 500 mcg/day or its equivalent (GINA 2019 table) at screening.

7. Pregnant or breastfeeding women or a woman who has a planned pregnancy during the course of the study. Menstruating females must have a negative pregnancy test at screening. Pregnancy testing may be conducted prior to procedures as well at various times in the study.

8. Subjects with household or close contacts who are pregnant or planning a pregnancy during the main subject's participation, who have chronic respiratory disease, who are children under the age of 2 years, or who are adults over 60 years of age or are Immunosuppressed e.g. post-chemotherapy, HIV) .

9. Subjects who provide healthcare services or work with elderly or children (e.g. daycare provider, senior citizen care giver).

10. Subjects who have received immunosuppressive treatment within the last 12 months

11. BMI is greater than 35

12. History of symptoms consistent with a viral URI within the past 21 days

13. Family history or medical history of liver disease or bleeding disorders

14. Have not received systemic corticosteroids for 3 months prior to Screening

15. Have an ACT score >19 at the time of enrollment.

16. Antiplatelet agents other than aspirin

17. Subjects who have a positive COVID-19 test will be excluded for 8 weeks

Related Conditions & MeSH terms

• Allergic Rhinitis
• Asthma
• Cat Allergy
• Healthy
• Rhinitis
• Rhinitis, Allergic

Intervention

Biological:
• Research Grade RG-RV
Exploration of the effects of RV inoculation on human airway mucosal programming in vivo

Locations

Country	Name	City	State
United States	University of Texas Medical Branch	Galveston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Medical Branch, Galveston

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ZEB-1 Expression	Q-PCR	Immediate
Primary	Type III Interferon	Q-RT-PCR	Immediate
Primary	PD-L1 Expression	Q-RT-PCR	Immediate
Primary	RV16 Viral Titer	Plaque Assays	48 hours after inoculation
Secondary	CD8 T cells in bronchoalveolar lavage fluid	Proportion and number of CD8+ T cells	Immediate and 48hrs post RV16 inoculation
Secondary	Airway Remodeling	Lamina reticularis thickness	Immediate and 48 hrs post RV16 inoculation
Secondary	URI Cold Symptoms	WURSS21 Questionnaire	Immediate and up to 7 days following inoculation